Open-label single-group study (n=10) assessing feasibility, safety, and preliminary efficacy of a single 25 mg oral psilocybin dose with preparatory and integration therapy for UCSD physicians with burnout.
This open-label feasibility study will enrol ten University of California, San Diego physicians experiencing persistent burnout to evaluate safety, tolerability, and preliminary clinical response to psilocybin-assisted therapy (PAT). Participants will receive preparatory psychological sessions, a single 25 mg oral dose of synthetic psilocybin, and post-dosing integration sessions.
Outcomes include feasibility and safety measures, change in burnout measured with the Stanford Professional Fulfillment Index, and exploratory neurophysiological assessments to identify brain changes associated with treatment response.
Single-group open-label administration of a 25 mg oral synthetic psilocybin dose combined with preparatory and integration therapy.
Synthetic psilocybin, single 25 mg dose with psychological support.